Love this new move adding the new director to replace Dr K. On the board. Every move since NP left is an upgrade. Dr K can now focus on the day to day operation of getting this drug approved while the new board member brings a vast and deep background as an ex CEO of pharmas that have been acquired as well as significant board experience. This is a no brainer ..